REG - Genedrive PLC - Director/PDMR Shareholding
04/04/2022 17:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220404:nRSD2148Ha&default-theme=true
RNS Number : 2148H Genedrive PLC 04 April 2022
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient
molecular diagnostics company, announces the following transaction by PDMRs.
The Company has granted share options ("Options") to Russell Shaw, CFO
Designate and a PDMR, to acquire a total of 100,000 ordinary shares of 1.5p
each ("Ordinary Shares") in the Company under the Company's Share Option
Scheme.
The Options have been granted with an exercise price of 30p per share equating
to the closing price on the day before the grant and vest after a period of
three years, subject to certain performance criteria being met through
achieving revenue targets, achieving cash targets and completing certain
strategic projects in the year ending June 2024. The Options are exercisable
over the period of 10 years from the date of grant.
In addition, Matthew Fowler, outgoing CFO and a PDMR, has today exercised
264,046 Options over Ordinary Shares at a price of 30.5p and following this
exercise he subsequently sold 264,046 Ordinary Shares at a price of 36.5p per
share. Following the above transaction Matthew Fowler has an interest in
52,500 Ordinary Shares.
Application has been made for 264,046 Ordinary Shares to be admitted to
trading on AIM ("Admission"). Admission is expect to occur on 8 April 2022
and the Ordinary Shares will, on issue, rank pari passu in all respects with
the Company's existing Ordinary Shares.
On Admission, the Company will have a total of 92,534,946 Ordinary Share in
issue. No Ordinary Shares are held in treasury. The figure of 92,534,946
may be used by the Company's shareholders as the denominator in the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure, Guidance and Transparency Rules.
The information set out below is provided in accordance with the requirements
of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. Details of the person discharging managerial responsibilities / person closely
associated
a. Name 1. Russell Shaw
2. Reason for the notification
a. Position/status 1. CFO Designate
a. Initial notification Initial notification
/Amendment
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name genedrive plc
b. LEI 213800ZYODIRZ87Y4K14
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the Options over ordinary shares of 1.5 pence each
Financial instrument, type
of instrument
Identification code
GB00B1VKB244
b. Nature of the transaction Grant of options pursuant to and in accordance with the terms of the
Company's Share Option Scheme dated 29 November 2017
c. Price(s) and volume(s)
Option price(s) Volume(s)
30p 100,000
d. Aggregated information
Aggregated volume N/A
Price
e. Date of the transaction 2022-04-04
f. Place of the transaction Outside a trading venue
d.
Aggregated information
Aggregated volume
Price
N/A
e.
Date of the transaction
2022-04-04
f.
Place of the transaction
Outside a trading venue
1. Details of the person discharging managerial responsibilities / person closely
associated
a. Name 1. Matthew Fowler
2. Reason for the notification
a. Position/status 1. Outgoing CFO
a. Initial notification Initial notification
/Amendment
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name genedrive plc
b. LEI 213800ZYODIRZ87Y4K14
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the Exercise of Options over ordinary shares of 1.5 pence each and sale of
ordinary shares of 1.5p each
Financial instrument, type
of instrument
Identification code
GB00B1VKB244
b. Nature of the transaction Exercise of options pursuant to and in accordance with the terms of the
Company's Share Option Scheme dated 29 November 2017 and subsequent sale of
ordinary shares
c. Price(s) and volume(s)
Option exercise price No. of options exercised
30.5p 264,046
Sale price No. of ordinary shares sold
36.5p 264,046
d. Aggregated information
Aggregated volume Gross proceeds realised of £96,376.79
Price
e. Date of the transaction 2022-04-04
f. Place of the transaction Outside a trading venue and Aim for the disposal
Sale price No. of ordinary shares sold
36.5p 264,046
d.
Aggregated information
Aggregated volume
Price
Gross proceeds realised of £96,376.79
e.
Date of the transaction
2022-04-04
f.
Place of the transaction
Outside a trading venue and Aim for the disposal
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel
finnCap (Joint Broker) +44 (0)20 7220 500
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAKLLEFAAEFARecent news on Genedrive
See all newsREG - AIM - AIM Notice - 15/05/2024
AnnouncementREG - Genedrive PLC - Amendment to Open Offer timetable
AnnouncementREG - Genedrive PLC - Publication of Circular and Notice of GM
AnnouncementREG - Genedrive PLC - Completion of placing
AnnouncementREG - Genedrive PLC - Proposed Fundraise for a minimum of £6.0 million
Announcement